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Abstract
Background: Individual patient data (IPD) meta-analysis is considered the “gold standard” for exploring the
effectiveness of interventions in different subgroups of patients. However, obtaining IPD is time-consuming and
contact with the researchers responsible for the original trials is usually required. To date, there are no studies
evaluating different strategies to optimize the process for retrieval of IPD from such researchers. Our aim is to
examine the impact of providing incentives to the researchers responsible for the trials eligible for a meta-analysis
to submit their IPD.
Methods/Design: We updated our previously published systematic reviews for type 1 diabetes mellitus comparing
long- and intermediate-acting insulin regimens (from January 2013 to June 2015) and for Alzheimer’s dementia
comparing cognitive enhancers (from January 2015 to May 2015). Eligible were randomized controlled trials (RCTs)
fulfilling the eligibility criteria of the systematic reviews. We will randomly allocate authors of the reports of these
RCTs into an intervention or control group. Those allocated to the intervention group will be contacted by email,
mail, and phone, and will be asked to provide the IPD from their RCT and will be given a financial incentive.
Those allocated to the control group will be contacted by email, mail, and phone, but will not receive a financial
incentive. Our primary outcome will be the proportion of authors who provide the IPD. The secondary outcomes
will be the time to return the dataset (defined as the period between the information request and the authors’
response with the dataset), and completeness of data. We will compare the response rates in the two groups using
the odds ratio and the corresponding 95 % confidence interval. We will also use binary logistic regression and cox
regression analyses to examine whether different RCT characteristics, such as study size and sponsor information,
influence the probability of providing IPD and the time needed to share the data.
Discussion: This study will determine whether a financial incentive affects response rates when seeking IPD from
the original researchers. We will disseminate our findings in an open access scientific journal and present results at
national and international conferences.
Trial registration: This trial is registered in Clinical Trials.gov, ID number NCT02569411. Date of registration 5
October 2015.
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retrieval, Data collection, Response rate
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Background
Over the past 30 years, there has been a considerable in-
crease in the number of published systematic reviews and
meta-analyses [1, 2], and systematic reviews have become
the base unit for developing clinical practice guidelines as
well as other knowledge tools used in clinical practice and
policy-making. Conducting a meta-analysis requires acces-
sing relevant outcome measurements from the individual,
eligible studies. However, often outcome data from eligible
studies are not available, as many authors do not report
them in their manuscript.
Medical journals have attempted to deal with this diffi-
culty by endorsing standards for reporting of study results,
such as the Consolidated Standards of Reporting Trials
(CONSORT) checklist [3]. Despite these efforts, it has been
shown that study data are inconsistently reported; missing
evidence is a substantial problem and one of the greatest
threats to the validity of results from a systematic review
and meta-analysis [4–6]. Authors of systematic reviews,
therefore, have to contact authors of the original studies to
attempt to obtain the relevant data for their analysis. How-
ever, authors of the original studies may be unwilling or
unable to share their data [7] and hence, systematic review
authors may have to exclude these studies from the meta-
analysis. This inability to obtain data occurs frequently,
and it might occur for a variety of reasons. For example,
the original study authors may worry that a re-analysis
might show an error or a pattern they missed [8], they may
have limited publication rights for the data as a study spon-
sor owns them [9], they may have moved to a different uni-
versity and lost the data, or the data might be old and
saved in an inaccessible storage device [10].
Meta-analysis can be conducted using individual patient
data (IPD) (data from each individual participant enrolled
in each included trial) and/or aggregated data (summary
point estimates from all participants enrolled in each in-
cluded trial). Meta-analysis of IPD is considered the “gold
standard” approach [11] for meta-analysis, in part because
it provides the opportunity to explore differences in treat-
ment effects across different subgroups. These subgroups
might include subsets of patients, such as males and fe-
males, or subsets of studies, such as those conducted in dif-
ferent geographical locations [12]. Knowledge about the
effectiveness of interventions in different subgroups is par-
ticularly important for decision- making. To date, there has
been an increase in the frequency of published IPD meta-
analyses [13], but authors of these studies (or data man-
agers) may have to devote a lot of time and effort to obtain
and prepare the IPD in the required format [14]. For in-
stance, a previously conducted IPD meta-analysis of 19
studies included four research coordinators (who invested
between 5 and 20 % of their full time) required 2088 hours
of data management and more than 1000 emails between
research coordinators and the data managers [15]. A main
barrier to undertaking an IPD meta-analysis is that study
authors usually report aggregated data, and IPD can only
be obtained by contacting the original study authors for in-
formation that they did not include in their reports. Al-
though there is a strong movement to share anonymized
IPD from randomized controlled trials (RCTs) [16–19], this
has not yet been well-established and the cooperation of
the original study authors is crucial for providing the data
in a usable format and answering queries about their data.
For example, a recent planned IPD meta-analysis failed to
be conducted, as the majority of the primary study authors
did not share their data [20]. Given that obtaining IPD is
important but also time-consuming, efforts need to be
undertaken to understand how to optimize this process.
Although previous studies have shown that financial incen-
tives may improve response rates in survey requests
[21–24], to the best of our knowledge there are no
studies evaluating whether a financial incentive may
facilitate the retrieval of IPD from authors of studies
that are eligible for a systematic review.
The objective of our study is to examine the impact of
providing a financial incentive to authors of RCTs that are
eligible for a systematic review and meta-analysis, versus
usual contact strategies to obtain the IPD. This trial proto-
col is in accordance with the Standard Protocol Items:
Recommendations for Interventional Trials (SPIRIT) 2013
statement [25] and is registered in ClinicalTrials.gov with
NCT02569411 (5 October 2015).
Methods
Study design
Our study will be a pragmatic (or effectiveness) RCT com-
paring the financial incentive (i.e., intervention) against
the standard process of contacting authors to obtain IPD
(i.e., control). The participants will be the authors of RCTs
included in our two systematic reviews for type 1 diabetes
mellitus [26] and for Alzheimer’s dementia [27], and we
will randomize these authors in two groups to request
their IPD (see Control and intervention groups section).
We updated the literature search for our published sys-
tematic reviews for type 1 diabetes mellitus [26] from Janu-
ary 2013 to June 2015, and for Alzheimer’s dementia [27]
from January 2015 to May 2015. Briefly, we used the terms
from our previous reviews to search MEDLINE, Cochrane
Central Register of Controlled Trials, and EMBASE. Gray
literature (i.e., difficult to locate and unpublished studies)
was searched via trial registry websites, relevant society/as-
sociation websites and conference abstracts. Reference lists
of included studies and relevant reviews were also scanned.
We used the Synthesi.SR tool [28] to screen citations and
full-text articles. To ensure reliability, we conducted a train-
ing exercise before screening titles and abstracts using our
eligibility criteria. When high agreement (greater than
90 %) was observed, two team members screened each title
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and abstract for inclusion, independently (level 1). After
pilot-testing, the same reviewers independently screened
the full text of potentially relevant articles to determine
inclusion (level 2). Conflicts were resolved by team
discussion.
In the type 1 diabetes study, we included trials study-
ing adults (aged 18 years or older) with type 1 diabetes
and comparing long-acting basal insulin analogue
preparations with other long- or intermediate-acting
insulin. We included RCTs of any duration reporting
glycosylated hemoglobin and severe hypoglycemia out-
comes. Our updated search identified 179 citations
with 15 potentially eligible studies, whereas 4 RCTs
met the inclusion criteria. In total, 30 RCTs were in-
cluded in the updated type 1 diabetes study, where 30
studies evaluated glycosylated hemoglobin and 24
assessed severe hypoglycemia.
In the Alzheimer’s dementia systematic review, we in-
cluded adults (aged 18 years or older) with Alzheimer’s
dementia diagnosed using various criteria (e.g., Diagnos-
tic and Statistical Manual of Mental Disorders, Nursing
Minimum Data Set criteria). Again, we focused on RCTs
of any duration and we included the Mini-mental State
Examination and overall serious adverse events out-
comes. Our updated search identified 73 citations with
12 potentially eligible studies, whereas 1 RCT met the
inclusion criteria. Overall, 108 RCTs were eligible for the
updated Alzheimer’s dementia review, where 74 studies
provided data on the Mini-mental State Examination
outcome and 64 provided data on the serious adverse
events outcome.
Participant recruitment
Corresponding authors of RCTs included in our previous
and updated systematic reviews will be eligible for inclu-
sion. We will attempt to obtain IPD from all eligible
studies by contacting the corresponding author of each
included RCT. In cases where the identified studies do
not report authors’ email addresses or include non-
working email addresses, we will search authors’ publica-
tions, PubMed, and profiles that are publicly available,
including Research Gate and Google Scholar, to find
contact information.
A challenge of this approach is that each author can
only be contacted to ask for IPD from a single study. If a
corresponding author of an eligible study has published
more than one study, we will contact the first, last or the
next in order author as presented in the paper. If a sin-
gle author is included in more than one paper, then we
will only contact him/her once for the newest study and
the older study will be excluded. In such a case, for the
IPD review and at the end of the RCT, we will contact
the authors in the same way to obtain the IPD for all ex-
cluded studies. All authors who provide feedback during
the conduct of the updated systematic review and IPD
network meta-analysis for the type 1 diabetes study and
the Alzheimer’s dementia study, will become part of an
active collaboration and will be included in the author-
ship in the final publication (only if they agree) [29, 30].
This is in accordance with the International Committee
of Medical Journal Editors (ICMJE) criteria [31]. A
CONSORT flow diagram depicting the process of the
study is presented in Fig. 1 [3]. This flow chart will be
updated showing the flow of participants in the entire
trial in the main manuscript.
Randomization and blinding
Eligible authors will be randomized to one of the two
trial groups using a 1:1 procedure. Randomization will
be performed using a computer-generated random num-
ber list, and adequate allocation concealment will be en-
sured as the sequence will not be revealed until the end
of the study. The computer randomization will be done
centrally and conducted by a statistician (AAV) who will
be blinded to the authors’ names. However, it is impos-
sible to blind the corresponding authors and research
personnel who will be in contact with them due to the
nature of intervention. Blinding of outcome assessors is
also not possible in this design.
Control and intervention groups
Control group
We will contact authors of eligible studies on Alzhei-
mer’s dementia and type 1 diabetes allocated to the con-
trol group to participate using four strategies, as per
Dillman’s method [21] to optimize response rates and
obtain IPD. First, authors will be sent an email request-
ing their IPD. Second, we will send four email reminders
at 2-, 6-, 10-, and 14-week intervals after the initial
email. Third, in week 7, we will send a reminder by post
in addition to email. Fourth, in week 15 we will attempt
to contact the corresponding author by phone. The dur-
ation of our study will be 19 weeks in total (see Fig. 2).
Intervention group
Using the same approach used for the control group, we
will contact authors using the four approaches described
above. Authors allocated to the intervention group will
be additionally provided with a financial incentive
(CAD100). Each participant allocated to the intervention
group will receive an upfront CAD100 incentive as a gift
certificate from Amazon (www.amazon.com) with the
first email notification. In the same email we will clarify
that at the end of the RCT, we will offer the same finan-
cial incentive to the authors allocated to the control
group.
We will send two different letters by email, one for
each group, simultaneously to the authors. The same
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letters will be sent to the authors’ mail addresses, which
will have been printed in two different files, one for each
group. In both letters, we will ask authors of the original
studies to be included in the group authorship on the
understanding that they provide feedback on results and
take part in writing and reviewing the systematic review
manuscript for the final publication, as is common prac-
tice in collaborative IPD reviews [32–35]. At the end of
the RCT, we will send a debriefing letter to all the au-
thors who participated to our study. All authors who will
share their data with us will be appropriately cited and
they will be acknowledged in our final manuscript if they
wish.
Outcomes
Our primary outcome will be the proportion of RCT
authors included in our published systematic reviews
who provide complete IPD. We will define complete
IPD as information on population, interventions, out-
comes and randomization as outlined below for the
two reviews:
1) Population: the type 1 diabetes RCTs should
include: age, sex, pregnancy, initial baseline
glucose control (e.g., baseline glycosylated
hemoglobin level), presence of comorbid
conditions, previous history of hypoglycemia,
other medications used for each participant, drop-
outs along with reasons for drop-out, and number
of participants, and Alzheimer’s dementia RCTs
should include: age, sex, severity of the Alzhei-
mer’s dementia, previous response to treatment
for Alzheimer’s dementia, presence of behavioral
disturbance, comorbid conditions (e.g., stroke),
other medications used for each patient, drop-
outs along with reasons for withdrawal, and num-
ber of participants
Fig. 1 Consolidated Standards of Reporting Trials (CONSORT) flow diagram of the process of the randomized controlled trial
Fig. 2 Study process flow diagram
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2) Interventions: including allocated treatment and
dosage
3) Outcomes: including event and date of event for
severe hypoglycemia in the type 1 diabetes review
and serious adverse events in the Alzheimer’s
dementia review, as well glycosylated hemoglobin
and Mini-mental State Examination values and
measurement dates for type 1 diabetes and Alzhei-
mer’s dementia respectively
4) Date of randomization for each participant and
overall method of randomization for all study
participants
If any of the above items are not provided in the data
we receive, but have been collected according to the
RCT’s protocol, the study’s dataset will be considered
partially complete. These items were chosen as the most
vital data for IPD analyses based on input from clinicians
on the relevant systematic review team.
Our secondary outcomes will be the time taken to ob-
tain the dataset and the completeness of data. We will
determine the duration between the information request
and the authors’ provision of their dataset to estimate
the time required to obtain data from authors. In case
the authors send multiple datasets (e.g., first received
dataset is incomplete, but after exchanging several
emails the final received dataset is complete) over a
period of time, we will consider the last date of corres-
pondence to estimate the time required to obtain IPD.
The completeness of the received dataset is crucial to in-
vestigators, as missing data might prevent inclusion of a
RCT in the meta-analysis. An IPD meta-analysis may be
biased if it is based only on a subset of trials [13]. If an
RCT author provides us with the requested information,
but some variables are missing (e.g., age, sex, pregnancy)
because these were not collected during the RCT, then
we will consider the dataset complete if this was re-
ported in the study protocol. This is because the data
are not missing due to selection bias. However, in case
the requested information is not provided and the data
have been collected in the RCT, the dataset will be con-
sidered incomplete. In such cases, we will not be able to
control for these variables for the particular RCT in the
analysis.
Ethical approval and confidentiality
Ethical approval for this RCT was obtained from the
Research Ethics Board (Dr. David Mazer, Dr. Philip
Berger, and Dr. Brenda McDowell) of St. Michael’s
Hospital (see Appendix).We are conducting the RCT
to examine the impact of incentivizing authors versus
usual contact strategies to obtain original IPD, and we
feel that disclosing this early on in a consent letter will
bias our results. Instead, we intend to send authors a
debriefing letter after they share their data with us,
letting them know that they were part of an RCT and
that they can withdraw their data from our analysis, if
they wish. The information generated during our
study will be confidential and limited to the purposes,
as described in this protocol. We will request authors
to share anonymized IPD only, where each patient will
be linked to a specific identifier.
Power and sample size
A sample size of at least 116 participants in total (58 per
group) for evaluation will provide 80 % power at the 5 %
level of significance (two-sided) to detect an increase in
response rates from 30 % in the control group to 55 %
in the experimental group with 1:1 allocation. This is
based on studies examining response rates of surveys.
We anticipate a large response difference (i.e., absolute
increase of 25 %) between the two groups as large and
upfront incentives have been shown to be more effective
than no, small or promised monetary incentives [36–39].
James et al. [36] compared survey response rates be-
tween US$25 prepaid and US$25 promised and found
that upfront payment of a cash incentive was signifi-
cantly more effective (odds ratio (OR) 2.88, 95 % confi-
dence interval (CI) (1.70, 4.89)). Similarly, Pit et al. [38]
conducted a pairwise meta-analysis comparing monetary
incentives versus no incentives in survey responses and
found that cash incentives were more effective at in-
creasing response rates (OR = 1.87, 95 % CI (1.55, 2.26)).
Our response rate estimate for the control arm (30 %)
was based on previous empirical findings for retrieval of
missing data in meta-analysis [40]. We expect to have
adequate power for a 25 % response difference between
the groups, as the current number of authors to contact
is 138 (i.e., 30 authors to contact for the type 1 diabetes
systematic review and 108 authors for the Alzheimer’s
dementia systematic review). We have experience in
contacting authors, as this is a regular process to ask for
additional aggregated data on the eligible studies to en-
hance clarity in a meta-analysis, and on average we have
a good response rate (over 60 %).
Data collection, management and statistical analysis
Two team members (AAV, HA) will independently as-
sess the data retrieved to ensure the datasets are
complete as defined in the Outcomes section. The as-
sessment process will be done blind to the allocation
using a computer-generated random number list. Con-
flicts will be resolved by discussion or involvement of a
third member (SES, ACT). All IPD will be held on a
password-protected database on a secure server at St.
Michael’s Hospital. Access to data and authors’ re-
sponses will be restricted to the research team and will
not be shared with any third parties.
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The analysis will be performed on an intention-to-
treat basis and participants will be analyzed in the arms
they were allocated to, regardless of whether they
received the intervention or not. Results will be reported
according to the CONSORT statement [3]. We will de-
scribe the two groups in terms of their baseline charac-
teristics, including sex (in RCTs the investigators are
focused on the sex of the patient (biological) and not
gender) of authors contacted, sponsor information, study
size, risk of bias, treatments compared, magnitude and
statistical significance of the treatment effect (as pre-
sented in the published trial), year of publication, coun-
try in which the study was conducted (according to first
author), and journal in which the study was published,
irrespective of whether the authors provided their IPD.
The funding source will be categorized as: (1) industry-
sponsored trials (funded by or authored by an employee
of a pharmaceutical or other commercial organization),
(2) publicly-sponsored trials (governmental sources and
non-profit organizations, including universities, hospi-
tals, and foundations), and (3) non-sponsored trials (no
funding source) [41]. We will also categorize studies ac-
cording to their sample size as small (fewer than 50 pa-
tients per arm), moderate (50–150 patients per arm),
and large (more than 150 patients per arm) [42]. Similar
to our previous systematic review [26], we will appraise
the risk of bias using the Cochrane Risk of Bias tool
[43]. Two investigators (HA and AAV/ACT) will inde-
pendently assess the risk of bias in each included study,
and any disagreements will be resolved by discussion
with a third investigator (SES). If risk of bias is unclear,
we will ask the author for clarification. Risk of bias will
be assessed considering direct investigation of the IPD
as described in the Preferred Reporting Items for Sys-
tematic Reviews and Meta-Analyses (PRISMA) exten-
sion to IPD checklist [44]. For example, randomization
might seem of low risk of bias in the text, but when
assessing this using IPD it might show that there is an
unbalanced treatment allocation to groups, and vice
versa. We believe that a small study size and high risk of
bias are factors that may impact on the IPD retrieval.
In this RCT, we will summarize categorical data in
each group using frequencies and percentages and 95 %
CIs, and we will use the chi-square test or Fisher’s exact
test as appropriate to compare them. The continuous
characteristics of each group will be presented using
means and 95 % CIs if approximately normally distrib-
uted, and medians and interquartile ranges (IQRs) if
non-normally distributed. We will compare means of
the two groups using the t test, and medians of the
intervention groups using the Wilcoxon-Mann-Whitney
test. We will also use summary statistics, e.g., OR for di-
chotomous data, mean difference for symmetrical con-
tinuous data, and ratio of geometric means for skewed
continuous data, along with the corresponding 95 % CI.
We will use the Shapiro-Wilk test to determine normal-
ity for each variable.
The primary data analysis will compare responses with
complete IPD between experimental and control groups
using ORs and corresponding 95 % CIs. We will calcu-
late the OR for response as soon as we have completed
all different strategies to contact the eligible authors, as
describe in the control and intervention groups section.
For the secondary outcome (time needed to share the
data), we will calculate the mean and 95 % CI for both
control and experimental groups, and then we will com-
pare them using mean difference and 95 % CI. We will
also describe the completeness of each study’s dataset
using percentages and 95 % CIs, and compare the aver-
age completeness of IPD between groups using mean
difference and 95 % CI. If authors are lost to follow-up
(e.g., they promise they will share the data and we never
hear back from them), a sensitivity analysis will be
undertaken using a complete case analysis to assess the
robustness of the findings with respect to missing data
for all outcomes.
To examine whether different study characteristics in-
fluence the probability of providing complete IPD as
specified in the primary outcome, we will use binary lo-
gistic regression adjusting for any confounding variables
(e.g., small study size, high risk of bias, funding) as ap-
propriate. We will start with bivariate regression analyses
(including one dependent and one independent variable)
and then for significant moderators we will simultan-
eously enter them into multiple regression models as
long as the minimum number of cases per independent
variable is 10. The significance of the variables in the
model will be evaluated with the Wald chi-square test
and determination of ORs with the associated 95 % CIs.
Similarly, to investigate the potential influence of the
aforementioned confounding variables on the secondary
outcome time needed to share the data, we will apply a
Cox regression model adjusting for these explanatory
variables. Statistical significance will be assessed at the
0.05 level (two-tailed). All statistical analyses will be con-
ducted by the lead author (AAV).
Discussion
To date, there has been a steady increase in publication
of systematic reviews that conduct an IPD meta-analysis
[13], but obtaining IPD is time-consuming and costly,
and depends on the authors’ willingness to share their
data. Reviewers who wish to complete an IPD meta-
analysis are often not able to obtain the IPD of all stud-
ies, and hence results might be prone to several biases
[14, 45, 46]. To the best of our knowledge, this is the
first experimental study that explores the effects of a
cash incentive to encourage authors of eligible studies to
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submit their IPD. Results of this study will establish
feasibility and provide evidence on the level of response
with respect to different study characteristics. In
addition, we will capture the most optimal and practical
strategies for maximizing the amount of IPD obtained.
Previous research evaluating the influence of financial
incentives on survey requests showed that such incen-
tives improve response rates considerably (average im-
provement between 15 and 19 %) [21–24]. This is
particularly important, as the study’s sample may not be
random according to the patient population, which may
result in biased study results and conclusions. A limita-
tion of this study is that we used survey research to in-
form our sample size, as to the best of our knowledge
there are no studies assessing response rate in retrieving
IPD from collaborative studies using financial incentives.
Findings of our study will contribute to the future plan-
ning of IPD meta-analyses given that the IPD retrieval is
part of their research process. We will be able to provide
guidance on ways that IPD might be obtained. This re-
search will help customize approaches to planning and
conducting IPD meta-analyses, including estimation of
the time needed and effective ways to collect the IPD. This
will help reviewers to effectively plan their timelines,
which may increase the use of IPD in meta-analysis and
network meta-analysis. We will disseminate the results of
this study in an open access scientific journal and present
our results at conferences.
Trial status
As of October 2015, we have updated the literature
searches, and finalized the screening process for our sys-
tematic reviews, and randomized the authors of the eli-
gible studies. We plan to start contacting the authors in
the beginning of February 2016.
Appendix
Ethical approval obtained from the Research Ethics
Board to conduct this randomized controlled trial.
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